<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Lilly&#x27;s Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naïve CLL/SLL — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Lilly&#x27;s Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naïve CLL/SLL</h2>
    <div class="badge">2025-09-08T10:45:00+00:00</div>
    <ul>
      <li>Serious ARs occurred in 56% of patients.</li>
<li>Sepsis (6%) and febrile neutropenia (4%) occurred.</li>
<li>Mantle Cell Lymphoma Serious ARs occurred in 38% of patients.</li>
<li>The most frequent malignancy was non-melanoma skin cancer (4.6%).</li>
<li>Bleeding of any grade, excluding bruising and petechiae, occurred (17%).</li>
<li>ARs resulting in permanent discontinuation in &gt;1% of patients included pneumonia.</li>
<li>Grade 4 decreased neutrophils (14%) and Grade 4 decreased platelets (6%) developed.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Lilly&amp;#x27;s Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naïve CLL/SLL\n• Serious ARs occurred in 56% of patients.\n• Sepsis (6%) and febrile neutropenia (4%) occurred.\n• Mantle Cell Lymphoma Serious ARs occurred in 38% of patients.\n• The most frequent malignancy was non-melanoma skin cancer (4.6%).\n• Bleeding of any grade, excluding bruising and petechiae, occurred (17%).\n• ARs resulting in permanent discontinuation in &gt;1% of patients included pneumonia.\n• Grade 4 decreased neutrophils (14%) and Grade 4 decreased platelets (6%) developed." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/lillys-jaypirca-pirtobrutinib-first-only-104500259.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>